Background: The occurrence of brain metastases (at diagnosis or at relapse) in patients with Wilms tumor is very rare.
INTRODUCTION
The remarkable success in the treatment of patients with Wilms tumor has meant that only a small proportion of patients develop disease relapse following initial therapy. 1 The most common site of relapse in children with Wilms tumor is lung followed by abdomen/flank and liver.
In contrast to other pediatric renal malignancies, such as clear cell sarcoma of the kidney (CCSK) 2 and rhabdoid tumor of the kidney (RTK), 3 Abbreviations: CCSK, clear cell sarcoma of the kidney; NWTS, National Wilms Tumor Study; RTK, rhabdoid tumor of kidney; SIOP, International Society of Paediatric Oncology; UKCCSG, United Kingdom Childhood Cancer Study Group where brain is a frequent metastatic site, recurrence in the brain is very rare in children with Wilms tumor. 4 Limited information is available on patients with Wilms tumor and brain metastases. Until the mid-1990s, data were available only through case reports or inclusive series describing childhood cancer intracranial metastases. [5] [6] [7] [8] [9] Only two series have been published from large cooperative groups describing a total of 21 patients. A retrospective review of the United Kingdom Children's Cancer Study Group (UKCCSG) trials described seven children with intracranial metastases; all registered on their first three Wilms tumor studies (1980) (1981) (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) . 4 Three of the seven were alive at the time of publication. 1971 and 2000 who developed subsequent intracranial relapse died. 10 Given its rarity, the optimal treatment of children with Wilms tumor who develop intracranial relapse is not known. To better understand the clinical characteristics, treatment used, and outcomes of patients with Wilms tumor and brain metastases, we undertook a retrospective review of patients enrolled on the National Wilms Tumor Studies (NWTSs).
MATERIALS AND METHODS
The database of patients enrolled on NWTS 1-5 was queried for patients with favorable or anaplastic Wilms tumor and metastases to the brain, either at diagnosis or at relapse. Patients with CCSK, RTK, renal cell carcinoma, and other renal neoplasms were excluded.
Patients were initially treated according to their stage and histology following one of the standard NWTS regimens. [11] [12] [13] [14] [15] [16] Clinical details at diagnosis and information on treatment outcome were reported on checklists, narratives, and flow sheets submitted by the pediatric oncologist, surgeon, and pathologist involved in the actual care of the patient.
Descriptive statistics (frequency and percentage for categorical characteristics; median and range for numerical characteristics) were used. The primary endpoint for evaluation was survival after intracranial relapse. The Kaplan-Meier method was used to construct the survival curve, with the standard error computed using the Peto-Peto method. 17 The overall survival from the time of intracranial relapse between the NWTS-5 and NWTS 1-4 patients was compared using log-rank test. In 30 patients (67%), the appearance of intracranial disease was preceded by relapse at another site (lungs in 21, lungs and bone in 4, lungs and liver in 2, liver only in 1, abdomen in 2). In seven patients, the intracranial relapse occurred simultaneously with relapse at another 
RESULTS

Patient characteristics
Treatment
Of the 45 patients with intracranial metastases, 19 patients did not undergo any surgical procedure and 11 patients underwent a biopsy only ( Table 2) . Surgical resection was attempted in 15 patients; gross total resection was achieved in 11 patients. Wilms tumor metastases were confirmed by pathological examination in 24 patients; biopsy was nondiagnostic in two patients.
Twenty-nine patients received brain irradiation; dosing information was available on 24 patients. The median whole brain radiation dose was 3,000 cGy (range 1,080-4,000 cGy). Four patients received additional boost to tumor bed. Twenty-seven patients received chemotherapy. The choice of chemotherapy was determined by previous treatment regimens. The chemotherapy agents used included vincristine, doxorubicin, ifosfamide, etoposide, carboplatin, cyclophosphamide, and cisplatin. Four patients underwent high-dose chemotherapy followed by autologous bone marrow transplant. Overall, 10 patients did not have any disease-directed therapy (surgery, chemotherapy, or irradiation) after the detection of intracranial disease; one each in NWTS-1 and -2, three each in NWTS-3 and -4, and two in NWTS-5.
Outcome
Nine patients (20%) were alive at last follow-up (Table 3 ). The median follow-up (from brain relapse) of surviving patients was 140 months (range 35-381 months). The median time to develop intracranial metastases in surviving patients was 17 months (range 3-37 months).
All survivors had favorable histology Wilms tumor at initial diagnosis. In four patients, brain metastases developed at the time of first relapse; in two of them, brain was the only site of relapse. Both of these patients underwent gross total resection of the tumor. All surviving patients received whole brain irradiation, with some patients receiving additional boost to tumor sites. One patient with isolated brain metastases underwent gross total resection and brain irradiation and did not receive chemotherapy. Other patients received regimens consisting of etoposide (n = 7), cyclophosphamide (n = 5), carboplatin (n = 5), ifosfamide (n = 2), vincristine (n = 2), and cisplatin (n = 1). Two patients underwent additional autologous bone marrow transplant with melphalan-based conditioning regimens.
Thirty-six patients (80%) were dead at last follow-up. Of these, 33 patients died due to progressive Wilms tumor in the brain or other parts of the body. One patient died due to cardiac arrest during brain biopsy. Two patients died due to likely complications of therapy 341 and 348 months after developing intracranial metastases; one patient died of refractory seizures and the other of glioblastoma multiforme. Both patients were treated with whole brain irradiation (3,000 and 4,000 cGy, respectively) and chemotherapy for their intracranial relapse. After the development of intracranial disease, 10 patients (22%) died within 1 month and 28 patients (62%) died within 1 year.
The 5-year overall survival from the time of intracranial relapse was 28.7% with the 95% confidence interval between 14.4 and 43.1% (Fig. 2) . Of the 14 patients who developed brain metastases in NWTS-5 study, seven (50%) were alive. Of the 31 patients who developed brain 
DISCUSSION
Approximately 0.5% of the patients with Wilms tumor enrolled in NWTS 1-5 developed intracranial relapse, confirming the rarity of the brain as a metastatic site. 4, 10 The incidence of intracranial relapse has remained relatively constant over time despite improvements in therapy and overall prognosis. This contrasts with the situation in CCSK, where the prevalence of intracranial metastasis has increased over time. 18, 19 The reason for this is unclear, but it is possible that improved therapy has led to better control of extracranial sites, allowing brain metastases to become manifest in a subgroup of patients with CCSK.
This phenomenon does not appear to be the case for Wilms tumor.
Similar to what was observed in the UKCCSG study, 4 we found that more boys developed intracranial recurrence than girls. In contrast, the SIOP study reported more central nervous system relapse in girls than in boys. 10 Overall, the data published in the literature thus far do not suggest a preponderance of either sex. of approximately 50%. [21] [22] [23] The lung is by far the most common site of relapse. Some studies suggest that relapse outside the lung is associated with unfavorable prognosis relative to lung-only relapse. 22 In the present series, the 5-year overall survival estimate from the time of brain recurrence was only 28%. While this is inferior to the survival rate for recurrent Wilms tumor in general, the data span a broad time period from NWTS 1-5. The prognosis seems to be improving with advances in multimodality therapy, as 50% of the patients with intracranial relapse in the most recent NWTSG study (NWTS-5) were alive compared with 6% previously (P = 0.03), mirroring the improvement in survival after relapse in general that has occurred over time.
The reason for this improvement in survival is likely multifactorial, including the availability of more chemotherapy agents, improvements in surgical and radiation techniques, and the recognition that some patients with recurrent disease can be salvaged.
The clinical characteristics of the nine surviving patients were evaluated to identify potential prognostic factors for patients with Wilms tumor and brain metastases (Supplementary 1). In general, prognostic factors described for relapsed Wilms tumor that convey poor outcome include early relapse, higher initial stage, anaplastic histology, and combined local and distant relapse. 16, 21, 24 Although it is difficult to draw firm conclusions based on the small patient group reported here, histology would seem to be an important factor for outcome because The NWTS experience presented does not allow formulating a conclusive therapeutic strategy for intracranial relapse. The therapies administered varied because this study spans a 30-year period in which several therapeutic changes were introduced. Nevertheless, it is noteworthy that only two of the nine salvaged patients had a gross total tumor resection. The UKCCSG investigators also reported survival after incomplete resection, as only one of the three surviving patients had undergone a complete resection. 4 Together these data would suggest that excision may not be necessary for salvage. Radiotherapy on the other hand seems indicated, as all nine survivors in the present series as well as the three survivors reported by UKCCSG received radiotherapy. However, the optimal dose of radiation is not known.
Moreover, there is concern about the long-term effects of radiation therapy in young children as exemplified by the death of one of our patients nearly 30 years after cranial irradiation due to the development of glioblastoma multiforme. The current Children's Oncology Group Wilms tumor protocols recommend whole brain irradiation to a dose of 3,060 cGy for older children after surgical resection. In radiosensitive cancers like leukemia and medulloblastoma, a prophylactic whole brain radiation dose of 1,800-2,300 cGy has been shown to be effective. In order to reduce late toxicity in young children with
Wilms tumor, especially those under 3-5 years of age, with a limited number of metastases, it is reasonable to reduce the whole brain dose to 2,160 cGy followed by a limited volume (tumor or tumor bed only with 0.5 cm margin) boost dose of 1,080 cGy using conformal irradiation or intensity-modulated radiation therapy. Chemotherapy was administered to eight of the nine survivors, although the exact role of chemotherapy in this context remains to be ascertained. A majority of the patients received cyclophosphamide, etoposide, and carboplatin. The same agents are effective against recurrent Wilms at other sites. 22 The utility of autologous bone marrow transplant in relapsed Wilms tumor is unknown. A meta-analysis of published studies suggested a benefit of high-dose therapy in patients with "very high risk" relapses, a group largely composed of patients who received four or more chemotherapy agents for up-front therapy. 25 Its role in patients with Wilms tumor relapsing to the brain could not be determined in this study. Although two of the four patients who underwent autologous bone marrow transplantation survived, they likely represent a selected population, as autologous bone marrow transplantation is often performed in the minimal residual disease setting.
In conclusion, relapse to the brain is a rare occurrence in patients with Wilms tumor. This report is the largest report to date on clinical outcomes of children with Wilms tumor and brain metastases.
Unlike intracranial metastases in other pediatric solid tumors, which are typically associated with rapid deterioration, intracranial relapse in Wilms tumor may be curable in patients with favorable histology Wilms tumor. A multimodality treatment approach including radiation therapy, chemotherapy, and surgery, if feasible, is recommended.
